相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ribosomopathies: human disorders of ribosome dysfunction
Anupama Narla et al.
BLOOD (2010)
Azacitidine for the Treatment of Lower Risk Myelodysplastic Syndromes
Pellegrino Musto et al.
CANCER (2010)
Deregulation of innate immune signaling in myelodysplastic syndromes is associated with deletion of chromosome arm 5q
Daniel T. Starczynowski et al.
CELL CYCLE (2010)
Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes
Carla Heise et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2010)
Lenalidomide for Treatment of Myelodysplastic Syndromes: Current Status and Future Directions
Rami S. Komrokji et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2010)
Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells
A. Pellagatti et al.
LEUKEMIA (2010)
A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q-syndrome
Jillian L. Barlow et al.
NATURE MEDICINE (2010)
Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype
Daniel T. Starczynowski et al.
NATURE MEDICINE (2010)
Persistent Malignant Stem Cells in del(5q) Myelodysplasia in Remission
Ramin Tehranchi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Van-den Berghe's 5q-syndrome in 2008
Azim Mohamedali et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
The Heterogeneous Prognosis of Patients With Myelodysplastic Syndrome and Chromosome 5 Abnormalities How Does It Relate to the Original Lenalidomide Experience in MDS?
Hagop Kantarjian et al.
CANCER (2009)
Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism
Laure Escoubet-Lozach et al.
CANCER RESEARCH (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer
B. L. Ebert
LEUKEMIA (2009)
CELL BIOLOGY Arrest by ribosome
Sebastien Ferreira-Cerca et al.
NATURE (2009)
A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide
Sheng Wei et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen
Benjamin L. Ebert et al.
NATURE (2008)
Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects
Kelly A. McGowan et al.
NATURE GENETICS (2008)
An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome
Benjamin L. Ebert et al.
PLOS MEDICINE (2008)
α-catenin is essential in intestinal adenoma formation
Hiroyuki Shibata et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Gene expression profiling of CD34+ cells in patients with the 5q-syndrome
Jacqueline Boultwood et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
The human Shwachman-Diamond syndrome protein, SBDS, associates with ribosomal RNA
Karthik A. Ganapathi et al.
BLOOD (2007)
Common deleted genes in the 5q-syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice
S. Lehmann et al.
LEUKEMIA (2007)
Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders
John M. Joslin et al.
BLOOD (2007)
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients
Andrea Pellagatti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells
Dominique Verhelle et al.
CANCER RESEARCH (2007)
Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation
Ting Xi Liu et al.
NATURE MEDICINE (2007)
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
Alan List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Gene expression profiles of CD34+ cells in myelodysplastic syndromes:: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype
Andrea Pellagatti et al.
BLOOD (2006)
Protein phosphatase 2A stabilizes human securin, whose phosphorylated forms are degraded via the SCF ubiquitin ligase
Ana M. Gil-Bernabe et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q
Stephen D. Nimer
JOURNAL OF CLINICAL ONCOLOGY (2006)
Loss of Hspa9b in zebrafish recapitulates the ineffective hematopoiesis of the myelodysplastic syndrome
SE Craven et al.
BLOOD (2005)
Efficacy of lenalidomide in myelodysplastic syndromes
A List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents
JB Bartlett et al.
NATURE REVIEWS CANCER (2004)
The Treacher!Collins syndrome (TCOF1) gene product is involved in ribosomal DNA gene transcription by interacting with upstream binding factor
BC Valdez et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Egr1 promotes growth and survival of prostate cancer cells - Identification of novel Egr1 target genes
T Virolle et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Mutations in SBDS are associated with Shwachman-Diamond syndrome
GRB Boocock et al.
NATURE GENETICS (2003)
Narrowing and genomic annotation of the commonly deleted region of the 5q-syndrome
J Boultwood et al.
BLOOD (2002)
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
FE Davies et al.
BLOOD (2001)
Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase
DV Bulavin et al.
NATURE (2001)
Hyperproliferation and defects in epithelial polarity upon conditional ablation of α-catenin in skin
V Vasioukhin et al.
CELL (2001)
Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia
M Ridanpää et al.
CELL (2001)
Structure of the dimerization and beta-catenin-binding region of alpha-catenin
S Pokutta et al.
MOLECULAR CELL (2000)
分享论文
